Portal de Periódicos da CAPES

Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis

2017; Impact Journals LLC; Volume: 8; Issue: 54 Linguagem: Inglês

10.18632/oncotarget.21114

1949-2553

Xianyun Zhang, Chuntao Fang, Guangbo Zhang, Fujin Jiang, Lei Wang, Jianquan Hou,

Cancer Research and Treatments

// Xianyun Zhang 1, 2, * , Chuntao Fang 3, * , Guangbo Zhang 4 , Fujin Jiang 2 , Lei Wang 2 and Jianquan Hou 1 1 Department of Urology, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China 2 Department of Urology, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai’an, Jiangsu, China 3 Department of Gynaecology, The Affiliated Huai'an Hospital of Xuzhou Medical University, The Second People's Hospital of Huai'an, Huai’an, Jiangsu, China 4 Clinical Immunology Laboratory, First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China * These authors contributed equally to this work Correspondence to: Jianquan Hou, email: houjq01@163.com Keywords: B7-H3, solid tumor, survival, prognostic biomarker, meta-analysis Received: December 20, 2016 Accepted: September 03, 2017 Published: September 21, 2017 ABSTRACT Increasing evidence suggests B7-H3 is aberrantly expressed in various cancers, though its prognostic significance in solid tumors remains controversial. We therefore performed a meta-analysis to clarify the prognostic value of B7-H3 expression in human solid tumors. The PubMed and Embase databases were searched, and 28 studies involving 4623 patients were ultimately included in the analysis. Hazard ratios (HRs) with 95% confidence intervals (CIs) were utilized as effect estimates to evaluate the association between B7-H3 expression and overall survival (OS), progression-free survival (PFS) and recurrence-free survival (RFS). The pooled results showed B7-H3 was associated with poor OS (HR = 1.58; 95% CI: 1.32–1.90; P < 0.00001) and PFS (HR = 1.67; 95% CI: 1.05–2.65; P = 0.031), but not RFS (HR = 1.17; 95% CI: 0.89–1.53; P = 0.267). These results suggest B7-H3 is a negative predictor of OS and PFS in patients with solid tumors. B7-H3 may thus be a useful prognostic biomarker and therapeutic target for human solid tumors. However, further studies will be needed to more precisely determine the prognostic value of B7 H3 expression.